| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ca7c109e96ea002b896c90befc5cf334
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b057fddee6645785fc5df7006be3bb3 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4465
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4015 |
| filingDate |
2020-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de818a482b6fbe3d36fb346a78f7956b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3948fb5379a665c934100f498572a734
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e99dc5b98e36f92e59af6cb24a01962a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe666ca38ebcd28f270d39e742d30ab9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de0b43a75c5cacbd3c1672f286616ee1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9017245d14a376033b3c4010c70ca165 |
| publicationDate |
2021-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3908580-A1 |
| titleOfInvention |
(2,5-dioxopyrrolidin-1-yl)(phenyl)-acetamide derivatives and their use in the treatment of neurological diseases |
| abstract |
The first object of the invention is the compound of general formula (I) or pharmaceutically acceptable salts thereof. A second object of the invention is the use of compounds described by general formula (I) as active ingredient in pharmaceutical compositions for the treatment of epileptic seizures or neuropathic pain or migraine. |
| priorityDate |
2019-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |